Minoryx Therapeutics

Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Minoryx Therapeutics headquartered in Europe, operates in the Biotechnology, Health Care, Pharmaceutical, Medical, Genetics sector. The company focuses on Biotechnology and has secured $28.8B in funding across 200 round(s). With a team of 11-50 employees, Minoryx Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Minoryx Therapeutics, raised $1.9M. Discover more about their projects, partnerships, and impact on our platform.